Publication | Closed Access

Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC

Ruxolitinib OvercomesMedicinePharmacologyJak/stat PathwayAnti-cancer AgentTumor SuppressorCancer TreatmentOncologyCell BiologyLung CancerJak-stat Signaling Pathway